Skip to content
OpenCapital
Get started

Revvity RVTY Diagnostics — Segment research and development expenses

Similar metrics at other companies

Analog Devices logo
ADIReportable Segment — R&D
$150.19M+13.4%
Teledyne Technologies logo
TDYDigital Imaging — R&D
$52.4M+18.8%
Becton, Dickinson and Company logo
BDXMedical — Segment Research and Development as a Percent of Revenues
1.2%0.0pp
Biogen logo
BIIBReportable Segment — Research and development:
$172.8M-3.2%
MACOM Technology Solutions logo
MTSIReportable Segment — Research and development (1)
$59.07M+17.2%
Guardant Health logo
GHReportable Segment — Research and development expense
$76.59M+2.3%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%—
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:SegmentResearchAndDevelopmentExpenses.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's diagnostics — segment research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's diagnostics — segment research and development expenses?
Revvity (RVTY) reported diagnostics — segment research and development expenses of $26.21M in Q1 2026.
How has Revvity's diagnostics — segment research and development expenses changed year-over-year?
Revvity's diagnostics — segment research and development expenses increased by 3.7% year-over-year, from $25.27M to $26.21M.
What is the long-term trend for Revvity's diagnostics — segment research and development expenses?
Over 3 years (2022 to 2025), Revvity's diagnostics — segment research and development expenses has grown at a -6.9% compound annual growth rate (CAGR), from $128.16M to $103.58M.
What does diagnostics — segment research and development expenses mean?
Spending on innovation and new product development within the diagnostics segment.
How do you interpret diagnostics — segment research and development expenses?
Higher spending indicates a focus on future growth and competitive advantage, whereas lower spending may signal a focus on short-term profitability.
How does diagnostics — segment research and development expenses compare across companies?
Standard metric for life sciences and technology companies to measure innovation intensity.